---
title: How to Extend Your Runway in Regulated MedTech Development
description: Extend runway in MedTech without breaking MDR. What costs you can defer, what must stay, and how to stretch capital without losing compliance.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: extend runway MedTech regulated product development
canonical_url: https://zechmeister-solutions.com/en/blog/extend-runway-cost-saving-regulated-product
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# How to Extend Your Runway in Regulated MedTech Development

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **You cannot cost-cut your way out of MDR obligations, but you can sequence them. Extending runway in regulated MedTech means deferring discretionary R&D scope, using fractional specialist roles, building a lean QMS, and launching into one market first. While never touching the non-negotiable costs under MDR Article 10 and Annex I.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- MDR Article 10 obligations on the manufacturer are non-negotiable and cannot be cost-cut away without rendering the device illegal to place on the market.
- Notified Body fees, clinical evidence, risk management, and the core QMS under EN ISO 13485:2016+A11:2021 are fixed-cost floors for any Class IIa and above device.
- The biggest runway savings come from subtracting discretionary R&D scope, not regulatory scope.
- A fractional Person Responsible for Regulatory Compliance (PRRC) under MDR Article 15 is a legitimate way to cut fixed headcount cost at early stage.
- Single-market launch (one EU country, one language set, one clinical setting) can cut go-to-market cost by more than half compared to a pan-European launch.
- Anything labelled "compliance cost saving" that weakens your technical documentation, your Clinical Evaluation Report, or your PMS plan is not a saving. It is deferred failure.

## Why runway math is different in MedTech

In most startup sectors, runway is a simple function of burn divided by cash in the bank. You cut the nice-to-haves, you delay the expensive hires, you negotiate with your landlord, and you buy yourself another quarter.

In regulated MedTech, there is a floor under your burn that you cannot cross without breaking the law. The Medical Device Regulation (EU) 2017/745 imposes obligations on the manufacturer that apply the moment you intend to place a device on the EU market. Those obligations cost money. If you cut below the floor, you are not saving runway. You are building a device you cannot legally sell, which means you are burning runway faster, not slower.

Founders get this wrong in both directions. Some treat regulatory work as a cost centre to be trimmed ruthlessly, then discover six months before audit that half their technical documentation does not exist. Others treat every MDR line item as sacred and cannot explain to their board why they are spending fifty thousand euros on activities that have nothing to do with their Notified Body's expectations. Both failure modes are expensive.

The Subtract to Ship approach is different. You map every euro of planned spend against a specific obligation in the MDR text. If the spend is tied to an obligation, it stays. If it is not, it is a candidate for cutting, deferring, or substituting.

## What MDR actually requires you to spend on

MDR Article 10 lists the general obligations of the manufacturer. Read it once with a highlighter and you will have a list of cost items that cannot be avoided for any device above Class I.

Article 10 requires, among other things, that the manufacturer:

- Ensures the device is designed and manufactured in accordance with the requirements of the Regulation (Art. 10(1))
- Establishes, documents, implements, and maintains a risk management system as set out in Annex I Section 3 (Art. 10(2))
- Conducts a clinical evaluation in accordance with Article 61 and Annex XIV (Art. 10(3))
- Draws up and keeps up to date technical documentation in accordance with Annexes II and III (Art. 10(4))
- Establishes a quality management system as described in Article 10(9)
- Has the person responsible for regulatory compliance referred to in Article 15 (Art. 10(9), last subparagraph)

These are obligations, not suggestions. Every one of them maps to a real cost: staff time, external review, testing, documentation tools. The QMS obligation is typically discharged by conformity to EN ISO 13485:2016+A11:2021. The risk management obligation is typically discharged via EN ISO 14971:2019+A11:2021.

Once your device is on the market, Articles 83 to 86 impose post-market surveillance obligations that run for as long as the device exists. These are not one-time costs. Budget for them as ongoing opex, not a project line item.

## A worked example: Series A SaMD on 14 months of runway

A Class IIa Software as a Medical Device startup has 1.6 million euros in the bank, a burn of 140,000 euros per month, and a target CE mark date 18 months out. Runway is 11 months. The CFO wants a cost-cut plan that gets them to 14 months without delaying certification.

Here is how the numbers actually move when you look at what can and cannot be cut:

**What cannot move:**
- Notified Body application and review fees: circa 45,000 to 80,000 euros depending on NB
- Clinical Evaluation Report authoring and literature search: circa 25,000 to 50,000 euros
- QMS certification audit fees: circa 15,000 to 25,000 euros
- Cybersecurity evidence package: real cost, real effort
- PRRC availability under Article 15

**What can move without touching MDR obligations:**
- Second device variant scheduled for month 12: defer to post-CE
- US FDA 510(k) parallel submission: defer to post-CE
- Second clinical pilot site: defer or drop
- Full-time senior QA/RA hire: replace with fractional specialist for 9 months, then re-evaluate
- Multi-language IFU (French, Italian, Spanish): launch into one country first, one language, add others post-revenue
- Office lease upgrade: keep current lease

That list, worked through honestly, typically delivers 25 to 40 percent burn reduction without touching a single Article 10 obligation. The device still gets certified. The company still has cash. The founder did not cut regulatory scope. They cut market scope and product scope.

## The Subtract to Ship playbook for regulated runway

**Step 1: Build the obligation map.** For every line in your budget, write the MDR article or annex that justifies it. If you cannot cite one, the line is discretionary.

**Step 2: Freeze the obligation floor.** Any spend tied to Article 10, Article 15, Article 61, Annex I, or the QMS under EN ISO 13485 is off-limits for cutting. You can negotiate prices. You cannot skip work.

**Step 3: Subtract market scope before product scope, and subtract product scope before regulatory scope.** This is the single most important sequencing rule. Launching in Germany only, with one clinical workflow, targeting one user group, costs a fraction of launching across the EU with full feature parity. The MDR does not require you to launch in 27 countries. It requires you to comply in the countries where you place the device.

**Step 4: Use fractional specialists where the law allows.** MDR Article 15(1) permits the PRRC to be available through a contractual arrangement for micro and small enterprises. This is not a loophole. It is written into the Regulation. A fractional PRRC, a fractional QA manager, and a fractional clinical evaluator can cut six-figure annual headcount cost and still meet every obligation, provided the contracts are real, the competence is documented under EN ISO 13485 clause 6.2, and the availability is genuine.

**Step 5: Build a minimum viable QMS, not a future-proof one.** Many startups buy an enterprise eQMS on the theory that they will grow into it. Most do not need it for another two years. A document-controlled folder structure, a simple change control process, and a handful of templates is enough to pass Stage 1 and Stage 2 audits for a Class IIa device. Upgrade when scale requires it, not when a sales rep says so.

**Step 6: Defer the second device.** Every additional device or variant multiplies technical documentation effort, clinical evaluation scope, risk management files, and PMS obligations. Certify one first. Extend the portfolio once the first is generating revenue or has unlocked a new financing round.

**Step 7: Defer FDA to post-CE.** Running CE and FDA in parallel is a standard pattern for well-funded MedTechs. For runway-constrained startups, it doubles regulatory work at the moment you can least afford it. CE first, FDA after first revenue, is a legitimate sequencing choice.

**Step 8: Never cut clinical evidence or risk management.** These are the two line items that auditors will dismantle you on. Cutting them saves money this quarter and costs you the entire company next quarter when the Notified Body rejects your submission.

## The things you cannot cut and stay legal

Be blunt with your team and your board about the floor. It includes:

- Technical documentation per Annex II and III
- Clinical evaluation per Article 61 and Annex XIV
- Risk management per Annex I Section 3 and EN ISO 14971:2019+A11:2021
- QMS per Article 10(9) and EN ISO 13485:2016+A11:2021
- PRRC availability per Article 15
- Post-market surveillance per Articles 83 to 86 and Annex III
- GSPR conformity per Annex I
- Notified Body conformity assessment per the route chosen (Annex IX, X, or XI)

Any pitch deck or budget that hides one of these items is a pitch deck that will not survive due diligence.

## Reality Check
1. Can you point to a specific MDR article for every five-figure line item in your current budget?
2. Have you calculated the burn reduction available from deferring product scope, not regulatory scope?
3. Is your PRRC arrangement genuinely compliant with MDR Article 15, or is it a placeholder?
4. Have you priced a single-country, single-language launch against your current multi-country plan?
5. Are you running FDA and CE in parallel because the business needs it, or because it feels ambitious?
6. Does your QMS tool cost more than the problem it is currently solving?
7. Would your current runway survive a three-month Notified Body queue delay?
8. If a board member asked what would happen if you cut clinical evaluation spend by 50 percent, could you explain the specific Article 61 failure that would cause?

## Frequently Asked Questions

**Can I delay hiring a full-time PRRC to extend runway?**
Yes, if you qualify as a micro or small enterprise under MDR Article 15(1), a contracted PRRC is permitted. The contract must be real, the person must be genuinely available, and their competence must be documented in your QMS.

**Is it safe to cut Notified Body review time by sending a less complete submission?**
No. Incomplete submissions trigger deficiency rounds that cost more in delay and re-review fees than the original preparation work would have cost. A lean but complete submission is always cheaper than a padded incomplete one.

**Can I skip post-market surveillance until after launch to save money now?**
No. MDR Articles 83 to 86 require the PMS system to be in place before placing the device on the market, not after. Your PMS plan is part of the technical documentation the Notified Body will review.

**How much can single-market launch actually save?**
For a Class IIa device, launching in one country in one language with one clinical workflow typically costs 40 to 60 percent less than a pan-European launch. Before you factor in the sales and support cost differences.

**Is an enterprise eQMS ever worth it for a pre-revenue startup?**
Rarely. Most pre-revenue startups can discharge every QMS obligation with simple tools and good discipline. Upgrade when audit findings, team size, or multi-site operations actually require it.

**Does MDR allow me to outsource risk management to save costs?**
You can use external experts, but the manufacturer remains responsible under Article 10(2). Outsourcing transfers the work, not the liability.

## Related reading
- [Burn rate management for MedTech startups](/blog/burn-rate-management-medtech) – the numbers side of runway discipline
- [The true cost of CE marking: transparent breakdown](/blog/true-cost-ce-marking-transparent-breakdown) – what you are actually paying for
- [Minimum viable QMS under MDR](/blog/minimum-viable-qms) – how to build a QMS that passes audit without burning cash
- [PRRC options for startups](/blog/prrc-options-startups) – fractional, contracted, and in-house paths under Article 15
- [Minimum viable regulatory strategy for CE mark on limited resources](/blog/minimum-viable-regulatory-strategy-ce-mark-limited-resources) – the sequencing playbook

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 5, 10, 15, 61, 83-86; Annexes I, II, III, IX, XIV.
2. EN ISO 13485:2016+A11:2021. Medical devices. Quality management systems.
3. EN ISO 14971:2019+A11:2021. Medical devices. Application of risk management to medical devices.

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*